Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinopathy of Prematurity (ROP): full-pipeline trial registry
2 of 4 indexed Retinopathy of Prematurity (ROP) trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Retinopathy of Prematurity (ROP): 4 US clinical trials tracked, 2 recruiting.
Retinopathy of Prematurity (ROP) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alaska Blind Child Discovery, running 1 of these trials.
Enrollment posture brief
Registry condition retinopathy-of-prematurity-rop
OPEN 2 | RECR 50% | LATE 1 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Retinopathy of Prematurity (ROP) lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinopathy of Prematurity (ROP) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinopathy of Prematurity (ROP) is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
OHB Neonatology
NCT03253263
Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity
Vanderbilt University Medical Center
NCT06612541
ROP Check Database Premature Infant Outcomes
Alaska Blind Child Discovery
NCT07312669
Rainbow Extension Study
Novartis Pharmaceuticals
NCT02640664
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinopathy of Prematurity (ROP) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinopathy of Prematurity (ROP) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinopathy of Prematurity (ROP) page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Retinopathy of Prematurity (ROP) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alaska Blind Child Discovery sponsors the most Retinopathy of Prematurity (ROP) trials on record, review their full trial history before evaluating a specific study. See Alaska Blind Child Discovery's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinopathy of Prematurity (ROP) condition card totals 4 registered trials; most-linked intervention Ranibizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.